Apollo Global Management is negotiating to acquire Johnson & Johnson's DePuy Synthes orthopedics business for close to $20 billion, according to Bloomberg reporting. The discussions mark one of the largest healthcare carve-out attempts this year and the most significant device-sector transaction since Stryker's $5.4 billion acquisition of Vocera Communications in 2022. DePuy Synthes generated approximately $9.6 billion in revenue for J&J's MedTech segment in 2023, representing roughly 27% of the division's total sales.

Johnson & Johnson has been methodically restructuring since announcing its $16.6 billion consumer health spinoff into Kenvue in 2023. The company's April 2024 strategic review flagged orthopedics as non-core to its pharmaceutical and high-margin surgical robotics priorities. DePuy Synthes, acquired through the $21.3 billion Synthes purchase in 2012, competes in a commoditizing joint replacement market where ASP erosion has averaged 2.8% annually since 2019. Apollo's interest follows its $3.2 billion take-private of LifePoint Health in 2018 and its $1.7 billion investment in Cano Health last year, both healthcare services plays with operational improvement angles.

The transaction structure matters more than the headline number. If Apollo pursues a full buyout, the orthopedics unit will likely require $12-14 billion in leveraged financing, straining covenant capacity in a market where healthcare LBO multiples have compressed from 12.4x EBITDA in 2021 to 8.9x in Q4 2024. The alternative—a spinoff with Apollo taking a minority stake—would preserve J&J's tax efficiency while giving Apollo operational control through a GP structure similar to its partnership with Redwood Health in 2023. J&J's board has historically favored tax-free separations, and a Reverse Morris Trust transaction would allow the company to distribute DePuy shares to existing stockholders while Apollo injects growth capital.

Allocators should monitor three datapoints: the debt-to-EBITDA ratio Apollo proposes, whether the deal includes DePuy's $1.1 billion annual R&D budget, and how quickly integration with Apollo's existing healthcare portfolio companies begins. If the transaction closes as structured, expect Apollo to consolidate purchasing across its $14 billion healthcare book, targeting $400-600 million in annual synergies by 2027. The orthopedics device market is projected to grow at 4.2% CAGR through 2030, but margin defense depends on robotics integration and ASC channel expansion—two areas where Apollo has deployed capital repeatedly.

J&J's equity has traded sideways since the Kenvue separation, underperforming the S&P Healthcare Index by 780 basis points in 2024. A clean DePuy exit would unlock $18-22 billion in deployable capital for share buybacks or tuck-in acquisitions in immunology, where the company's Tremfya and Stelara franchises face biosimilar pressure starting in 2025. Apollo, meanwhile, continues to press into defensive healthcare assets as its $733 billion AUM base hunts yield in a narrowing credit environment.